Politiparty
Politiparty

118th Congress Health

H.R. 7539: LOANS for Biomedical Research Act

Introduced

  1. Introduced (completed)Mar 5, 2024
  2. Passed House (not reached)
  3. Passed Senate (not reached)
  4. To the President (not reached)
  5. Became law (not reached)

Summary

Introduced in House, Mar 5, 2024

This bill requires the Department of the Treasury to establish the BioBonds Program to support loans for clinical trials for eligible drugs and medical devices for unmet medical needs.

Under the program, fiscal agents purchase loans (up to $25 million per recipient) and issue collateralized bonds that are sold to investors and that are guaranteed by Treasury. An eligible borrower under this program is one conducting (or seeking to conduct) research related to a drug or device that is (1) intended to meet an unmet medical need; and (2) under investigation in certain types of controlled clinical trials, including a trial to investigate the safety and effectiveness of the drug or device.

The Government Accountability Office (GAO) and Treasury must report on the program; GAO must also study whether similar programs should be established for other biomedical research projects.

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Cosponsors

8

Bipartisan support.

Who scored on this bill

6 points earned
  1. 1Brian Fitzpatrick R-PA SponsorDrew cross-party cosponsors, introduced2 events+6
See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by Brian Fitzpatrick

History

  1. Mar 5, 2024Introduced in the House by Brian Fitzpatrick.
Show the full action history (3 actions)
  1. Mar 8, 2024Referred to the Subcommittee on Health.
  2. Mar 5, 2024Introduced in House
  3. Mar 5, 2024Referred to the House Committee on Energy and Commerce.